SOURCE: SciClone Pharmaceuticals, Inc.

November 03, 2005 06:30 ET

SciClone to Present at Rodman and Renshaw Techvest Healthcare Conference

SAN MATEO, CA -- (MARKET WIRE) -- November 3, 2005 -- SciClone Pharmaceuticals (NASDAQ: SCLN) today announced that it will present at the Rodman and Renshaw Techvest Healthcare conference at the New York Palace Hotel in New York. Ira D. Lawrence, M.D., SciClone's President and Chief Executive Officer, will deliver a corporate overview presentation on Monday, November 7, 2005 at 8:00 a.m. EST. The presentation may include forward-looking statements.

To access the live and subsequent archived audio webcast of the presentation, log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com. A replay of the webcast will be available for 30 days.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone's lead product ZADAXIN® is currently being evaluated in two phase 3 hepatitis C clinical trials in the United States and one hepatitis C triple therapy clinical trial in Europe. ZADAXIN also is being evaluated in other late-stage clinical trials for the treatment of hepatitis B and certain cancers. The company's other principal drug development candidate is SCV-07, currently in phase 1 development, which is being evaluated for the treatment of viral and other infectious diseases. For more information about SciClone, visit www.sciclone.com.

Contact Information

  • Corporate information contact:
    Becky Horner
    Investor Relations
    SciClone Pharmaceuticals, Inc.
    650-358-3437